Highlights
- Thyrocare Technologies shares declined 6.94% to close at ₹517.20 on Thursday.
- The stock witnessed profit booking after a strong rally in recent weeks.
- Elevated trading volumes accompanied the sharp correction during the session.
- The company remained profitable in its latest reported quarter.
- Despite the decline, the stock continues to trade above its 63-day moving average.
- Investors will monitor whether the stock stabilizes around key technical support levels.
Overview
Thyrocare Technologies Ltd. came under selling pressure during Thursday's trading session, with the stock falling 6.94% to close at ₹517.20 from the previous close of ₹555.80. The stock opened at ₹555.80, touched an intraday high of ₹558.50, and slipped to a low of ₹512.20 before recovering marginally by the close. The decline followed a strong rally in recent weeks, with higher trading volumes reflecting increased market participation during the correction.
Fundamental View
For the quarter ended 31 March 2026, Thyrocare Technologies reported standalone total income of ₹21,439.00 lakh. The company posted a profit before tax of ₹6,198.00 lakh and a net profit of ₹4,358.00 lakh, while earnings per share (EPS) stood at ₹2.75. The diagnostic services provider continues to strengthen its presence across preventive healthcare and pathology testing through its nationwide laboratory network. Investors are likely to monitor test volumes, expansion initiatives, and profitability trends in the coming quarters.
Technical View
Thyrocare Technologies witnessed a sharp pullback after an extended upward move in recent sessions. Although the stock corrected during the day, it continues to trade above its 63-day moving average, suggesting that the broader trend remains positive. The Relative Strength Index (RSI) has eased from higher levels following the decline, while elevated trading volumes indicate active market participation. The stock's ability to hold above nearby support levels will remain important for its short-term price structure.
Key Technical Levels
Immediate support is placed near ₹510.00, followed by the next support around ₹490.00. On the upside, immediate resistance is seen near ₹540.00, while the next resistance is positioned around ₹560.00. These levels are likely to influence the stock's near-term movement.
Risks to Watch
- Slower growth in diagnostic test volumes.
- Increasing competition in the diagnostics industry.
- Pricing pressure across healthcare services.
- Regulatory changes affecting the healthcare sector.
- Overall market volatility.
Summary
Thyrocare Technologies ended the session with a notable decline after witnessing profit booking following its recent rally. Despite the correction, the company continues to report healthy profitability, while the broader technical structure remains above its long-term moving average. Investors will closely monitor business growth, earnings performance, and whether the stock stabilizes near important support levels.
FAQs
Q: Why did Thyrocare Technologies shares fall today?
A: The stock declined following profit booking after a strong rally, with higher trading volumes reflecting increased market activity during the session.
Q: What was Thyrocare Technologies' closing price?
A: The stock closed at ₹517.20.
Q: How did the company perform in the latest quarter?
A: The company reported standalone total income of ₹21,439.00 lakh and a net profit of ₹4,358.00 lakh for the quarter ended 31 March 2026.
Q: What are the key technical levels for the stock?
A: Immediate support is near ₹510.00, while immediate resistance is around ₹540.00.
Q: What should investors monitor going forward?
A: Investors will watch diagnostic test volumes, profitability trends, expansion initiatives, and whether the stock holds above key support levels.